Uncommon esophagitis associated with nivolumab and ipilimumab therapy

Dig Endosc. 2021 Mar;33(3):467-468. doi: 10.1111/den.13902. Epub 2020 Dec 29.

Authors

Genki Inoue¹, Takahiro Utsumi¹, Akihiko Yoshizawa²

Affiliations

¹ Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

PMID: 33251627
DOI: 10.1111/den.13902

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Combined Chemotherapy Protocols
Esophagitis* / chemically induced
Esophagitis* / diagnosis
Humans
Ipilimumab / adverse effects
Melanoma* / drug therapy
Nivolumab / adverse effects

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Nivolumab